News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rexahn Pharmaceuticals, Inc. (RNN) Reports Second Quarter 2014 Financial Results And Pipeline Update


8/14/2014 8:11:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and financial results for the quarter ended June 30, 2014.

“We are pleased with the continued progress of the RX-3117, Supinoxin™ and Archexin® clinical development programs,” stated Rexahn’s Chief Executive Officer Peter D. Suzdak, PhD. “Positive data from these studies would be major milestones and will help direct the next steps for the Company.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES